1
|
Kuwano K, Shimizu S, Fujita Y, Akatsu S, Shibagaki Y, Yazawa M. Marked hyperkalemia due to inappropriate blood sample storage in two suspected cases of familial pseudohyperkalemia. CEN Case Rep 2023; 12:397-401. [PMID: 36907981 PMCID: PMC10620351 DOI: 10.1007/s13730-023-00781-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Accepted: 02/23/2023] [Indexed: 03/14/2023] Open
Abstract
We herein report two suspected cases of pseudohyperkalemia who presented with severe hyperkalemia examined at small primary care clinics; however, re-exams at a tertiary care hospital showed normal potassium levels. We reproduced the laboratory examination conditions of the clinics and found that hyperkalemia was due to sampling/storage condition of serum, which is strongly suggestive of familial pseudohyperkalemia (FP). FP is a possible but under-appreciated cause of hyperkalemia, which does not require treatment, so it is important to include FP in the differential diagnosis of hyperkalemia especially in cases with discrepant of serum potassium levels at different settings.
Collapse
Affiliation(s)
- Katsuhisa Kuwano
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan
- Department of Nephrology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki, 852-8501, Japan
| | - Sayaka Shimizu
- Institute for Health Outcome and Process Evaluation Research (I-Hope International), Shimomaruya-cho 403, Chukyo-ku, Kyoto, Japan
| | - Yoko Fujita
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan
| | - Satoshi Akatsu
- Department of Clinical Laboratory, St. Marianna University School of Medicine Hospital, 2-16-1, Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan
| | - Yugo Shibagaki
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan
| | - Masahiko Yazawa
- Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan.
| |
Collapse
|
2
|
Tone K, Gochi M, Kuwano K. Respiratory syncytial virus pneumonia in an immunocompetent adult: an important differential diagnosis of COVID-19. QJM 2022; 115:868-869. [PMID: 36000922 PMCID: PMC9452185 DOI: 10.1093/qjmed/hcac205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 08/18/2022] [Indexed: 12/15/2022] Open
Affiliation(s)
- K Tone
- Address correspondence to K. Tone, Department of Respiratory Medicine, The Jikei University School of Medicine Kashiwa Hospital, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan.
| | - M Gochi
- From the Department of Respiratory Medicine, The Jikei University School of Medicine Kashiwa Hospital, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan
| | - K Kuwano
- Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishishimbashi, Minato-ku, Tokyo 105-8471, Japan
| |
Collapse
|
3
|
Kuwano K, Ota Y, Tsuji K, Torigoe K, Yamashita A, Muta K, Kitamura M, Yamashita H, Uramatsu T, Tashiro M, Hayashi H, Izumikawa K, Mukae H, Nishino T. An Autopsy Case of Disseminated Varicella Zoster Virus Infection during the Treatment of Nephrotic Syndrome. Intern Med 2022; 61:571-576. [PMID: 34393162 PMCID: PMC8907779 DOI: 10.2169/internalmedicine.7332-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
A 68-year-old woman developed systemic blisters while receiving treatment for nephrotic syndrome. As she also developed marked liver dysfunction and disseminated intravascular coagulation, she was admitted to our hospital. She was diagnosed with varicella zoster virus (VZV) infection. Treatment was administered in the intensive-care unit, but the patient died on day 24 post-admission after severe VZV infection. A post-mortem examination showed micro-abscesses and necrosis caused by varicella zoster infection in multiple organs, including the liver, kidneys, and gastrointestinal tract. Because VZV infection can become severe in immunocompromised patients, careful consideration is needed for the prevention and treatment of the viral infection.
Collapse
Affiliation(s)
| | - Yuki Ota
- Department of Nephrology, Nagasaki University Hospital, Japan
| | - Kiyokazu Tsuji
- Department of Nephrology, Nagasaki University Hospital, Japan
| | - Kenta Torigoe
- Department of Nephrology, Nagasaki University Hospital, Japan
| | - Ayuko Yamashita
- Department of Nephrology, Nagasaki University Hospital, Japan
| | - Kumiko Muta
- Department of Nephrology, Nagasaki University Hospital, Japan
| | | | | | | | - Masato Tashiro
- Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Japan
| | - Hiroko Hayashi
- Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Japan
| | - Koichi Izumikawa
- Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Japan
| | - Hiroshi Mukae
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
| | - Tomoya Nishino
- Department of Nephrology, Nagasaki University Hospital, Japan
| |
Collapse
|
4
|
Matsutani H, Amano M, Izumi C, Baba M, Abe R, Hashiwada S, Kuwano K, Shimada M, Sakamoto J, Miyake M, Tamura T, Matsuo S. P1444 Occurrence and predictors of right ventricular dysfunction after pericardiocentesis. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background—The changes in cardiac function that occur after pericardiocentesis are unclear.Purpose—This study was performed to assess right ventricular (RV) and left ventricular (LV) function with echocardiography before and after pericardiocentesis.
Method and Results—In total, 19 consecutive patients who underwent pericardiocentesis for more than moderate pericardial effusion were prospectively enrolled from August 2015 to October 2017. Comprehensive transthoracic echocardiography was performed before, immediately after (within 3 hours), and 1 day after pericardiocentesis to investigate the changes in RV and LV function. RV dysfunction is defined as meeting three of the four criteria: a TAPSE of <17 mm, an S’ of <9.5 cm, an FAC of <35%, and an RV free wall longitudinal strain >−20%. The mean age of all patients was 72.6 ± 12.2 years. The changes of echocardiographic parameters related to RV function are shown in Table. After pericardiocentesis, RV inflow and outflow diameters increased and the parameters of RV function significantly decreased. These abnormal values or RV dysfunction remained at 1 day after pericardiocentesis. Conversely, no parameters of LV function parameters changed after pericardiocentesis. Of 19 patients, 13 patients showed RV dysfunction immediately after pericardiocentesis and 6 patients did not. RV free wall longitudinal strain before pericardiocentesis was higher in patients with post-procedural RV dysfunction (−18.9 ± 3.6%) than in those without (−28.4 ± 6.3%). ROC analysis revealed that a RV free wall longitudinal strain cut-off value of −23.0% had a sensitivity of 100% and a specificity of 83.3% for predicting the occurrence of RV dysfunction after pericardiocentesis (AUC = 0.910).
Conclusions—The occurrence of RV dysfunction after pericardiocentesis should be given more attention. Pre-existing RV dysfunction maybe related to the occurrence of RV dysfunction after pericardiocentesis.
Changes in RV function before and after Before Immediately after One day after P−value Basal right ventricular linear dimension (mm) 32.8 ± 5.0 37.1 ± 4.4† 33.6 ± 5.4 0.028 Mid-cavity right ventricular linear dimension (mm) 34.5 ± 4.6 38.8 ± 5.3† 37.0 ± 5.6 0.0504 Proximal right ventricular outflow diameter (mm) 30.2 ± 4.0 33.9 ± 3.5† 31.4 ± 3.9 0.014 TAPSE (mm) 20.0 ± 4.2 13.6 ± 4.3* 14.7 ± 3.9 <0.001 S" (cm/s) 12.6 ± 3.3 8.7 ± 2.4* 9.1 ± 2.4 <0.001 Fractional area change (%) 48.3 ± 5.9 37.8 ± 8.0* 40.0 ± 9.0 <0.001 Right ventricular free wall strain (%) −21.3 ± 6.3 −15.8 ± 6.7* −16.9 ± 5.2 0.036 Tricuspid regurgitation velocity peak (m/s) 2.41 ± 0.29 2.43 ± 0.25 2.34 ± 0.32 0.37
Collapse
Affiliation(s)
- H Matsutani
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - M Amano
- National Cerebral and Cardiovascular Center, Department of Cardiovascular Medicine, Osaka, Japan
| | - C Izumi
- National Cerebral and Cardiovascular Center, Department of Cardiovascular Medicine, Osaka, Japan
| | - M Baba
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - R Abe
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - S Hashiwada
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - K Kuwano
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - M Shimada
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - J Sakamoto
- Tenri Hospital, Department of Cardiology, Tenri, Japan
| | - M Miyake
- Tenri Hospital, Department of Cardiology, Tenri, Japan
| | - T Tamura
- Tenri Hospital, Department of Cardiology, Tenri, Japan
| | - S Matsuo
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| |
Collapse
|
5
|
Kazuyori T, Seki Y, Sato A, Fujimoto S, Yamada M, Yamanaka Y, Fujisaki I, Odashima K, Seki A, Ishikawa T, Kuwano K. P2.16-32 Best Supportive Care for Extreme Elderly Lung Cancer Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Sasaki S, Oikado K, Saito Y, Tominaga J, Sata M, Sakai F, Kato T, Iwasawa T, Kenmotsu H, Kusumoto M, Baba T, Endo M, Fujiwara Y, Sugiura H, Yanagawa N, Ito Y, Sakamoto T, Ohe Y, Kuwano K. Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Seki Y, Kazuyori T, Sato A, Fujimoto S, Yamada M, Yamanaka Y, Fujisaki I, Odashima K, Seki A, Ishikawa T, Kuwano K. P2.16-07 How to Manage Toxicities of EGFR-TKI for Extreme Elderly Lung Cancer Patients: Supportive Care for Patients Aged 85 and Older. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
8
|
Powell CA, Camidge DR, Gemma A, Kusumoto M, Baba T, Kuwano K, Bankier A, Kiura K, Tamura K, Modi S, Tsurutani J, Doi T, Iwata H, Krop IE, Zhang L, Jasmeet S, Saito K, Shahidi J, Yver A, Takahashi S. Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-06] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Several classes of anti-cancer agents including certain immunotherapies, systemic chemotherapies, and targeted therapies including trastuzumab and T-DM1 increase the risk of interstitial lung disease (ILD) and fatal cases have been reported. For DS-8201a, interim efficacy and safety analyses of available data established a final recommended dose of 5.4 mg/kg IV q3wk in advanced HER2-positive breast cancer (BC). Based on preliminary clinical results, ILD was identified as an important risk for DS-8201a. A robust monitoring and management plan was established across all studies and an international, independent ILD adjudication committee (AC) reviews the cases reported as ILD on an ongoing basis.
Methods: All subjects (sbj) who received ≥1 dose of DS-8201a across 7 ongoing studies were included in this analysis. Reported ILD (standardized MedDRA Query terms) included the terms ILD, pneumonitis, and organizing pneumonia. ILD frequencies were calculated based on investigator's assessment and after adjudication. The analysis of potential risk factors associated with ILD is ongoing.
Results: As of 21 June 2018, 448 sbj received ≥1 dose of DS-8201a across multiple tumor types, including BC. Of the 321 sbj with BC, 173 (53.9%) were from Japan, 103 (32.1%) from the US, and 45 (14.0%) from 6 other countries (Spain, South Korea, Taiwan, Belgium, France, and Italy). These sbj received 1 of 7 doses of DS-8201a (0.8 mg/kg: 3 sbjs, 1.6 mg/kg: 1 sbj, 3.2 mg/kg: 3 sbjs, 5.4 mg/kg: 111 sbjs, 6.4 mg/kg: 178 sbj, 7.4 mg/kg: 20 sbj, 8.0 mg/kg: 5 sbj). Overall, 44 cases of potential ILD were reported by the investigators across all tumor types (44/448, 9.8%; Grade ≥3 10/448, 2.2%). In sbj with BC who received 5.4 mg/kg, any grade and Grade ≥3 investigator-reported ILD were 7.2% (8/111) and 0.9% (1/111), respectively. The ILD AC assessed 30 of 44 cases; 22 were considered drug-related ILD, 4 were ILD but not drug-related, and 4 were found not to be ILD. For adjudicated drug-related ILD cases, the median time to onset was 159 (range; 46-591) days from the time of first dose.
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 All Grades All tumors, All doses (N=448) Investigator-reported20 (4.5)14 (3.1)4 (0.9)1 (0.2)5 (1.1)44 (9.8)Cases adjudicated13840530Adjudicated as drug-related ILD9 (2.0)6 (1.3)3 (0.7)04 (0.9)22 (4.9) BC, All doses (N=321) Investigator-reported17 (5.3)11 (3.4)3 (0.9)1 (0.3)4 (1.2)36 (11.2)Cases adjudicated11830426Adjudicated as drug-related ILD8 (2.5)6 (1.9)3 (0.9)04 (1.2)21 (6.5) BC, 5.4 mg/kg (N=111) Investigator-reported4 (3.6)3 (2.7)001 (0.9)8 (7.2)Cases adjudicated120014Adjudicated as drug-related ILD00001 (0.9)1 (0.9)n (%), except where noted
Conclusions: These analyses confirm that ILD is an important identified risk for DS-8201a. Further analyses are ongoing to better understand the potential risk factors associated with the incidence of on-treatment ILD. When ILD is suspected, early diagnosis through appropriate imaging, laboratory tests, and pulmonary consultation as well as prompt management with steroids are recommended.
Citation Format: Powell CA, Camidge DR, Gemma A, Kusumoto M, Baba T, Kuwano K, Bankier A, Kiura K, Tamura K, Modi S, Tsurutani J, Doi T, Iwata H, Krop IE, Zhang L, Jasmeet S, Saito K, Shahidi J, Yver A, Takahashi S. Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-06.
Collapse
Affiliation(s)
- CA Powell
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - DR Camidge
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Gemma
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - M Kusumoto
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Baba
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Kuwano
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Bankier
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Kiura
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Tamura
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Modi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - J Tsurutani
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Doi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - H Iwata
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - IE Krop
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - L Zhang
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Jasmeet
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Saito
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - J Shahidi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Yver
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Takahashi
- Icahn School of Medicine at Mount Sinai, New York, NY; University of Colorado Denver School of Medicine, Denver, CO; Nippon Medical School, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Jikei University School of Medicine, Tokyo, Japan; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; Okayama University Hospital, Okayama, Japan; Memorial Sloan-Kettering Cancer Center, New York, NY; Kindai University Faculty of Medicine, Osaka, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Dana-Farber Cancer Institute, Boston, MA; Daiichi Sankyo, Inc., Basking Ridge, NJ; Daiichi Sankyo Co., Ltd., Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| |
Collapse
|
9
|
Ohe Y, Gemma A, Nakagawa K, Yamamoto N, Saito T, Akamatsu A, Kuwano K, Nakanishi Y. Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.088] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Tada A, Ozaki A, Kuwano K, Morita T, Tanimoto T. Early goal-directed mobilisation after surgery. Lancet 2017; 389:695. [PMID: 28229869 DOI: 10.1016/s0140-6736(17)30335-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 11/10/2016] [Indexed: 11/29/2022]
Affiliation(s)
- Ayako Tada
- Department of Postgraduate Education, Kameda Medical Center, Chiba, 296-8602, Japan.
| | - Akihiko Ozaki
- Department of Surgery, Minamisoma Municipal General Hospital, Fukushima, Japan
| | - Katsuhisa Kuwano
- Department of Postgraduate Education, Nagasaki University Hospital, Nagasaki, Japan
| | - Tomohiro Morita
- Department of Internal Medicine, Soma Central Hospital, Soma, Japan
| | - Tetsuya Tanimoto
- Department of Internal Medicine, Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan
| |
Collapse
|
11
|
Seki Y, Fujiwara Y, Kohno T, Goto Y, Horinouchi H, Kanda S, Nokihara H, Yamamoto N, Kuwano K, Ohe Y. Analysis of circulating cell-free DNA in plasma shows a higher detection rate of EGFR mutations in patients with extrathoracic disease progression. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw393.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Kida Y, Taira J, Kuwano K. EprS, an autotransporter serine protease, plays an important role in various pathogenic phenotypes of Pseudomonas aeruginosa. Microbiology (Reading) 2015; 162:318-329. [PMID: 26678838 DOI: 10.1099/mic.0.000228] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Pseudomonas aeruginosa possesses an arsenal of both cell-associated (flagella, pili, alginate, etc.) and extracellular (exotoxin A, proteases, type III secretion effectors, etc.) virulence factors. Among them, secreted proteases that damage host tissues are considered to play an important role in the pathogenesis of P. aeruginosa infections. We previously reported that EprS, an autotransporter protease of P. aeruginosa, induces host inflammatory responses through protease-activated receptors. However, little is known about the role of EprS as a virulence factor of P. aeruginosa. In this study, to investigate whether EprS participates in the pathogenicity of P. aeruginosa, we characterized various pathogenic phenotypes of the wild-type PAO1 strain and its eprS-disrupted mutant. The growth assays demonstrated that the growth of the eprS mutant was somewhat lower than that of the wild-type strain in a minimal medium containing BSA as the sole carbon and nitrogen source. Thus, these results indicate that eprS would have a role in the growth of P. aeruginosa in the presence of limited nutrients, such as a medium containing proteinaceous materials as a sole nutrient source. Furthermore, disruption of eprS resulted in a decreased production of elastase, pigments, autoinducers and surfactants, and a reduction of swimming and swarming motilities. In addition, the eprS mutant exhibited a reduction in the ability to associate with A549 cells and an attenuation of virulence in leucopenic mice as compared with the wild-type strain. Collectively, these results suggest that EprS exerts pleiotropic effects on various pathogenic phenotypes of P. aeruginosa.
Collapse
Affiliation(s)
- Y Kida
- Division of Microbiology, Department of Infectious Medicine,Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011,Japan
| | - J Taira
- Department of Bioscience and Bioinformatics,Graduate School of Computer Science and Systems Engineering, Kyushu Institute of Technology, 680-4 Kawazu, Iizuka, Fukuoka 820-8502,Japan
| | - K Kuwano
- Division of Microbiology, Department of Infectious Medicine,Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011,Japan
| |
Collapse
|
13
|
Yamazaki T, Hirai C, Ota S, Kuwano K, Kuwano S. Use of FM1-43, a membrane-specific fluorescent dye, to estimate plasma membrane integrity in the cryopreservation of green algae. Cryo Letters 2014; 35:180-187. [PMID: 24997835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND AND OBJECTIVE Cryopreservation of microorganism cultures is an important technology for their use as biological and genetic resources; however, the procedure is complicated and depends on the species. MATERIALS AND METHODS We used the two-step freezing method for the cryopreservation of the green alga Parachlorella kessleri. RESULTS AND CONCLUSION The optimal cryoprotectant for cryopreservation was 5% dimethyl sulfoxide plus 5% ethylene glycol. This is different from the optimal cryoprotectant for the closely related species Chlorella vulgaris. Efficient cryopreservation of P. kessleri was achieved using methanol, similar to Chlamydomonas reinhardtii. A membrane-specific fluorescent dye, FM1-43, was applied to estimate plasma membrane integrity. We found that the plasma membrane integrity of P. kessleri cells after freeze-thawing was associated with survivability, suggesting that this is a useful index for the optimization of the first step of the two-step freezing method of cryopreservation.
Collapse
Affiliation(s)
- T Yamazaki
- Department of Integrated Biosciences, Graduate School of Frontier Sciences, University of Tokyo, Kashiwanoha, Kashiwa, Chiba, Japan. JST, CREST, Kashiwanoha, Kashiwa, Chiba, Japan. .-tokyo.ac.jp
| | - C Hirai
- Department of Integrated Biosciences, Graduate School of Frontier Sciences, University of Tokyo, Kashiwanoha, Kashiwa, Chiba, Japan
| | - S Ota
- Department of Integrated Biosciences, Graduate School of Frontier Sciences, University of Tokyo, Kashiwanoha, Kashiwa, Chiba, Japan. JST, CREST, Kashiwanoha, Kashiwa, Chiba, Japan
| | - K Kuwano
- Graduate School of Fisheries Science and Environmental Studies, Nagasaki University, Nagasaki , Japan
| | - S Kuwano
- Department of Integrated Biosciences, Graduate School of Frontier Sciences, University of Tokyo, Kashiwanoha, Kashiwa, Chiba, Japan. JST, CREST, Kashiwanoha, Kashiwa, Chiba, Japan
| |
Collapse
|
14
|
Kan-O K, Matsumoto K, Inoue H, Fukuyama S, Asai Y, Watanabe W, Kurokawa M, Araya J, Kuwano K, Nakanishi Y. Corticosteroids plus long-acting β2-agonists prevent double-stranded RNA-induced upregulation of B7-H1 on airway epithelium. Int Arch Allergy Immunol 2012; 160:27-36. [PMID: 22948082 DOI: 10.1159/000338430] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2011] [Accepted: 03/23/2012] [Indexed: 01/21/2023] Open
Abstract
BACKGROUND Airway viral infections provoke exacerbations of asthma and chronic obstructive pulmonary disease. B7-H1 is a costimulatory molecule that is implicated in an escape mechanism of viruses from host immune systems. This escape may be associated with the persistence of viral infection and lead to exacerbation of underlying diseases. We have shown that an analog of viral double-stranded RNA, polyinosinic-polycytidylic acid (poly IC), upregulated the expression of B7-H1 on airway epithelial cells, an effect which was corticosteroid-resistant. We investigated the effects of corticosteroids plus long-acting β(2)-agonists (LABAs; fluticasone/salmeterol or budesonide/formoterol) on the expression of B7-H1. METHODS BEAS-2B cells and primary airway epithelial cells were stimulated with poly IC or respiratory syncytial virus. The expression of B7-H1 was assessed by flow cytometry. RESULTS Poly IC upregulated the expression of B7-H1, which was suppressed by high-concentration corticosteroids but not by LABAs. The upregulation was suppressed by very low-concentration corticosteroids when used in combination with LABAs. Their combination also suppressed the virus-induced upregulation of B7-H1. Poly IC stimulation induced the nuclear translocation of nuclear factor ĸB (NF-ĸB). Inhibitors of NF-ĸB activation prevented the poly IC-induced upregulation of B7-H1. Low-concentration corticosteroids in combination with LABAs enhanced the de novo induction of IĸBα, the endogenous inhibitor of NF-ĸB activation. CONCLUSIONS Fluticasone/salmeterol or budesonide/formoterol attenuate the virus-associated upregulation of B7-H1 on airway epithelial cells via suppression of NF-ĸB activation.
Collapse
Affiliation(s)
- K Kan-O
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Takayama T, Kuwano K, Hirai D, Katsura Y, Yamamoto A, Takagi H. Strong coupling superconductivity at 8.4 K in an antiperovskite phosphide SrPt3P. Phys Rev Lett 2012; 108:237001. [PMID: 23003981 DOI: 10.1103/physrevlett.108.237001] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Revised: 03/23/2012] [Indexed: 06/01/2023]
Abstract
We report the discovery of a family of ternary platinum phosphides APt3P (A = Ca, Sr, and La), which crystallize in an antiperovskite-based structure closely related to that of the heavy fermion superconductor CePt3Si. All three phosphides showed superconductivity at low temperatures and the highest critical temperature T(c) = 8.4 K was observed for SrPt3P. The analysis of specific heat C(T) for SrPt3P shows clear evidence for very strong coupling s-wave superconductivity with a large ratio between superconducting gap Δ0 and T(c), 2Δ0/k(B)T(c) ∼ 5, and the presence of low-energy phonons. The presence of multiple Fermi surface pockets was inferred from the nonlinear magnetic field dependence of Hall resistivity, which we argue might play a role in realizing the strong coupling of charge carriers with the low-lying phonons.
Collapse
Affiliation(s)
- T Takayama
- Department of Advanced Materials, University of Tokyo, and JST-TRIP, Kashiwa, Chiba 275-8651, Japan
| | | | | | | | | | | |
Collapse
|
16
|
Abstract
Evidence that apoptosis plays an important role in the pathophysiology of lung diseases has been accumulated. Apoptosis signaling is classically composed of two principle pathways. One is a direct pathway from death receptor ligation to caspase cascade activation and cell death. Death receptor ligation triggers recruitment of the precursor form of caspase-8 to a death-inducing complex, through the adaptor protein FADD, which leads to caspase-8 activation. The other pathway triggered by stimuli such as drugs, radiation, infectious agents and reactive oxygen species is initiated in mitochondria. After cytochrome c is released into the cytosol from the mitochondria, it binds to Apaf1 and ATP, which then activate caspase-9. Recently, endoplasmic reticulum has also been shown to be the organelle to execute apoptosis. Further understanding of molecular mechanisms of apoptosis and its regulation by novel drugs may lead to the development of effective strategies against lung diseases. We overview the signaling pathways of apoptosis and discuss the involvement of apoptosis in the pathophysiology of various lung diseases.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan.
| | | | | | | | | | | |
Collapse
|
17
|
Nakashima N, Kuwano K, Maeyama T, Hagimoto N, Yoshimi M, Hamada N, Yamada M, Nakanishi Y. The p53-Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. J Clin Pathol 2005; 58:583-9. [PMID: 15917407 PMCID: PMC1770696 DOI: 10.1136/jcp.2004.022632] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Wild-type p53 is increased during cellular responses to various stresses. Mdm2, which is induced by p53, regulates p53 protein concentrations through the ubiquitin-proteasome pathway. AIM To investigate whether the Mdm2 mediated ubiquitination of p53 is associated with epithelial cell apoptosis in idiopathic pulmonary fibrosis (IPF). METHODS Immunohistochemistry and western blot analysis were carried out on lung samples obtained by lung biopsy from patients with IPF and non-specific interstitial pneumonia (NSIP). RESULTS The expression of p53, phosphorylated p53, Mdm2, p21, and Bax was upregulated in epithelial cells from patients with IPF and NSIP compared with normal lung parenchyma. Except for p21, there was a significant increase in the expression of these factors in IPF compared with NSIP. In addition, the number of apoptotic cells and the number of p53 and Bax positive cells was increased compared with controls. p53 conjugated with Mdm2 was decreased in IPF compared with NSIP and controls. Ubiquitinated p53 was increased in both IPF and NSIP compared with controls. CONCLUSIONS Signalling molecules associated with p53 mediated apoptosis may participate in epithelial cell apoptosis, and the attenuation of p53-Mdm2 conjugation and of p53 degradation may be involved in the epithelial cell apoptosis seen in IPF. Augmented epithelial apoptosis in IPF may lead to the poor prognosis compared with NSIP.
Collapse
Affiliation(s)
- N Nakashima
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Fukuoka 812-8582, Japan
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Miyazaki H, Kuwano K, Yoshida K, Maeyama T, Yoshimi M, Fujita M, Hagimoto N, Yoshida R, Nakanishi Y. The perforin mediated apoptotic pathway in lung injury and fibrosis. J Clin Pathol 2005; 57:1292-8. [PMID: 15563670 PMCID: PMC1770527 DOI: 10.1136/jcp.2003.015495] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
AIMS The perforin mediated pathway is the major pathway of cytotoxicity induced by activated T cells and natural killer cells, and may be involved in the development of pulmonary fibrosis. METHODS Perforin and granzyme B expression were examined in idiopathic pulmonary fibrosis by means of immunohistochemistry, and perforin knockout mice were used to examine whether or not perforin mediated cytotoxicity participates in the pathophysiology of bleomycin induced pneumopathy. RESULTS Perforin and granzyme B expression were upregulated in infiltrating lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis compared with normal lung parenchyma. Perforin and granzyme B expression were upregulated predominantly in infiltrating mononuclear cells after bleomycin instillation in wild-type mice. Although the development of bleomycin induced pneumopathy was not completely prevented, the pathological grade of inflammation and fibrosis, and the number of apoptotic cells in lung tissue, were significantly decreased in perforin knockout mice compared with wild-type mice. CONCLUSIONS These results suggest that perforin mediated apoptosis may be associated with the pathophysiology of lung injury and fibrosis.
Collapse
Affiliation(s)
- H Miyazaki
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Drugs have been implicated in lung injury as a result of direct pharmacological action, persistence or metabolism in the tissue, or via the production of a reactive metabolite or metabolites. The result of this apparent drug-associated injury ranges from cellular dysfunction through to cell death (apoptosis) and alteration of repair mechanisms that are essential in replacing critical tissue elements and function. There is limited knowledge on how timing of drug administration or drug interactions may interfere with the repair mechanisms or modulate the expression of pulmonary toxicity. Chemotherapeutic drugs and novel agents, such as those targeting the epidermal growth factor receptor (EGFR), appear to affect both normal and neoplastic cells. However, unlike chemotherapy, where the actions are systemic and directly as a result of biotransformation or cell injury, it has been postulated that effects of EGFR-targeting agents are more likely to be focused on epithelia via a pharmacological effect. Furthermore, risk factors for the development of adverse pulmonary reactions, as well as biological markers indicating incipient toxicity, need to be prospectively identified. Proteomics, through the identification of ⩾1000 proteins or peptides in blood samples, will hopefully identify candidates for this role.
Collapse
Affiliation(s)
- T Higenbottam
- Global Clinical Science, AstraZeneca R&D, Charnwood, Bakewell Road, Loughborough, Leicester LE11 5RH, UK.
| | | | | | | |
Collapse
|
20
|
Abstract
Pulmonary fibrosis is a common response to various injuries to the lung. The resolution of a fibroproliferative response after lung injury is key to survival. Although there are various initiating factors or causes, the terminal stages are characterized by proliferation and progressive accumulation of connective tissue replacing normal functional parenchyma. Conventional therapy consisting of glucocorticoids or immunosuppressive drugs is usually ineffective in preventing progression of fibrosis. Further understanding of the molecular mechanisms of endothelial and epithelial cell injury, inflammatory reaction, fibroblast proliferation, collagen deposition and tissue remodeling, should lead to the development of effective treatments against pulmonary fibrosis. Evidence that apoptosis plays an important role in the pathophysiology of pulmonary fibrosis has been accumulated. We overview the role of apoptosis in each of the pathogenic events which have emerged from animal models and human tissue studies.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | |
Collapse
|
21
|
Fujita M, Ye Q, Ouchi H, Nakashima N, Hamada N, Hagimoto N, Kuwano K, Mason RJ, Nakanishi Y. Retinoic acid fails to reverse emphysema in adult mouse models. Thorax 2004; 59:224-30. [PMID: 14985558 PMCID: PMC1746974 DOI: 10.1136/thx.2003.010785] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Previous work has shown that all-trans-retinoic acid reverses elastase induced emphysema in rats. Since there is currently no effective treatment for pulmonary emphysema, the effect of retinoic acid should be further investigated in other adult species. A study was undertaken using two murine models of emphysema to evaluate the effect of retinoic acid. METHODS The models used were an elastase induced emphysema model for acute alveolar destruction and a tumour necrosis factor (TNF)-alpha transgenic mouse which exhibits chronic air space enlargement, loss of elastic recoil, increased lung volume, and pulmonary hypertension comparable to human pulmonary emphysema. All-trans-retinoic acid (2 mg/kg) was injected for 12 successive days after the establishment of emphysema. The effects of treatment were evaluated using physiological and morphometric analyses. RESULTS In contrast to the rat, administration of all-trans-retinoic acid in these murine models did not improve the emphysema. Moreover, worsening of emphysema was observed in TNF-alpha transgenic mice treated with all-trans-retinoic acid. The level of keratinocyte chemoattractant (KC), a CXC chemokine, in bronchoalveolar lavage fluid was increased in TNF-alpha transgenic mice following retinoic acid treatment. These data raise the possibility that retinoic acid causes deterioration of emphysema by promoting inflammation in this model. CONCLUSIONS In these models, retinoic acid did not show positive effects on emphysema. The effect of retinoic acid in the treatment of pulmonary emphysema remains controversial, and further studies are required to determine its physiological effects under a variety of experimental conditions.
Collapse
Affiliation(s)
- M Fujita
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Kuwano K, Nakashima N, Inoshima I, Hagimoto N, Fujita M, Yoshimi M, Maeyama T, Hamada N, Watanabe K, Hara N. Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J 2003; 21:232-40. [PMID: 12608435 DOI: 10.1183/09031936.03.00063203] [Citation(s) in RCA: 94] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Lung epithelial cells are a primary target for reactive oxygen species (ROS). ROS can cause oxidative deoxyribonucleic acid modification, such as 8-hydroxy-deoxyguanosine (8-OHdG). A human homologue of the MutT protein (hMTH1) prevents this modification. Mitochondria are the most important cellular source of ROS and may be susceptible to oxidative damage. The purpose of this study is to investigate oxidative stress and mitochondrial damage in lung epithelial cells from idiopathic interstitial pneumonias (IIPs). The authors analysed 8-OHdG, hMTH1, and mitochondrial proteins on lung specimens from 13 patients with IlPs consisted of eight patients with usual interstitial pneumonia and five patients with nonspecific interstitial pneumonia using Western blot analysis and immunohistochemistry. Immunoreactivity for 8-OHdG and hMTH1 was significantly increased in the lung epithelial cells from patients with IIPs compared with controls. The expression of hMTH1 was localised in the nuclear and cytoplasmic, but not the mitochondrial, fraction of lung homogenates. Immunoreactivity for mitochondrial protein and cytochrome c oxidase complex subunit IV was increased in the lung epithelial cells from patients with IIPs compared with controls. The current study concludes that oxidative stress may participate in epithelial cell damage in idiopathic interstitial pneumonia, and that increased mitochondrial mass may associate with increased reactive oxygen species production in idiopathic interstitial pneumonia.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
The current authors have demonstrated previously that epithelial cell apoptosis, induced by the Fas-Fas ligand pathway, might be involved in fibrosing lung diseases. Whereas lung epithelial cells are sensitive to the Fas-mediated apoptosis, lung fibroblasts may be resistant to Fas-mediated apoptosis and replace damaged epithelial cells. The WI-38 lung fibroblast cell line and primary lung fibroblasts were used to examine the resistant to Fas-mediated apoptosis and the association of anti-apoptotic proteins with this resistance. The administration of agonistic anti-Fas antibody (CH-11) or cycloheximide alone did not induce apoptosis, whereas the co-administration of CH-11 with cycloheximide induced apoptosis in WI-38 cells, in which caspase-8 and -3, but not -9, were activated, and X chromosome-linked inhibitor of apoptosis (ILP) and FLICE-like inhibitor protein (FLIP(L)), but not bcl-xL and bcl-2, were remarkably down regulated. Primary lung fibroblasts were also resistant to Fas-mediated apoptosis, and ILP and FLIP appeared to be involved in this resistance. Furthermore, the results of immunohistochemistry demonstrated that fibroblasts expressed ILP and FLIP(L) proteins in lung tissues from patients with idiopathic pulmonary fibrosis. These results suggest that anti-apoptotic proteins such as X chromosome-linked inhibitor of apoptosis and FLICE-like inhibitor protein may play an important role in preventing Fas-mediated apoptosis in lung fibroblasts, and participate in the development of pulmonary fibrosis.
Collapse
Affiliation(s)
- T Tanaka
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | |
Collapse
|
24
|
Kunitake R, Kuwano K, Yoshida K, Maeyama T, Kawasaki M, Hagimoto N, Hara N. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration 2002; 68:488-95. [PMID: 11694811 DOI: 10.1159/000050556] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND KL-6, and surfactant protein A (SP-A) and surfactant protein D (SP-D) derived from alveolar type II cells and/or bronchiolar epithelial cells have been reported to be useful markers for interstitial lung diseases. OBJECTIVE The aim of this study was to measure the levels of these molecules in bronchoalveolar lavage fluid (BALF) from patients with pulmonary sarcoidosis to investigate their relationship with other markers of inflammatory activity. METHODS We measured KL-6, SP-A and SP-D levels in BALF from patients with pulmonary sarcoidosis using an ELISA. RESULTS KL-6 and SP-D, but not SP-A levels were significantly increased in pulmonary sarcoidosis compared with controls. KL-6, SP-A and SP-D levels were significantly correlated with each other. KL-6 and SP-D levels were relatively and significantly correlated with the percentage of lymphocytes in BALF. KL-6, SP-D, but not SP-A levels were significantly correlated with the concentration of albumin in BALF. There was no significant correlation between KL-6, SP-A, or SP-D levels and chest X-ray findings, angiotensin-converting enzyme levels, or CD4/CD8 ratio in BALF. CONCLUSIONS We conclude that KL-6 and SP-D levels in BALF were increased in pulmonary sarcoidosis. Since these markers are specifically derived from epithelial cells, it is considered that KL-6 and SP-D levels are reflecting damage or release of these markers from epithelial cells due to the inflammatory response.
Collapse
Affiliation(s)
- R Kunitake
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | |
Collapse
|
25
|
Tanaka A, Kuwano K, Matsuba T, Kawasaki M, Yoshida K, Hagimoto N, Hara N. [A case of sarcoidosis involving multiple organs that showed significant improvement as the serum KL-6 level fell after steroid therapy]. Nihon Kokyuki Gakkai Zasshi 2001; 39:915-9. [PMID: 11875807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/17/2023]
Abstract
Pulmonary sarcoidosis was diagnosed by transbronchial lung biopsy in a 27-year old man admitted to our hospital in September 1996. In October 1999, bilateral parenchymal findings on chest radiography and the results of pulmonary function tests had significantly deteriorated compared with those of three years before. Since skin, heart, liver, and spleen lesions were also detected, this patient was treated with corticosteroids. The lung parenchymal lesions and the pulmonary function as well as the abnormal findings in other organs showed significantly improvement along with a decrease of the KL-6 level after steroid therapy.
Collapse
Affiliation(s)
- A Tanaka
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashiku, Fukuoka 812-8582, Japan
| | | | | | | | | | | | | |
Collapse
|
26
|
Kida Y, Kuwano K, Zhang Y, Arai S. Acholeplasma laidlawii up-regulates granulysin gene expression via transcription factor activator protein-1 in a human monocytic cell line, THP-1. Immunology 2001; 104:324-32. [PMID: 11722647 PMCID: PMC1783303 DOI: 10.1046/j.1365-2567.2001.01310.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
An antimicrobial protein granulysin is constitutively expressed in cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. However, little is known about the precise regulatory mechanisms underlying granulysin gene expression. In this study, we examined the regulatory mechanisms underlying granulysin gene expression using a human monocytic cell line, THP-1, treated with Acholeplasma laidlawii. The level of granulysin mRNA expression in THP-1 cells was significantly augmented in response to stimulation with A. laidlawii. The transfection of reporter gene constructs into THP-1 cells indicated that DNA sequences between residues -329 and -239, relative to the transcriptional start site of the granulysin gene, are responsible for mediating gene induction. In addition, mutagenesis of a putative activator protein-1 (AP-1)-binding site between residues -277 and -271 in the granulysin promoter resulted in the reduction of granulysin promoter activity. Electrophoretic mobility shift assays (EMSA) demonstrated that nuclear extract prepared from A. laidlawii-treated THP-1 cells can generate specific binding to DNA oligonucleotides encompassing the AP-1-binding site, whereas unstimulated nuclear extract from the cells failed to do so. Furthermore, competition and supershift assays confirmed that A. laidlawii can induce the activation of AP-1. These results indicate that AP-1 dominantly participates in the regulation of inducible granulysin gene expression in THP-1 cells. Therefore, the finding of inducible granulysin gene expression by A. laidlawii suggests that inducible granulysin in macrophages may function as a protective weapon when microbial invasion occurs.
Collapse
Affiliation(s)
- Y Kida
- Department of Bacteriology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | | | | | | |
Collapse
|
27
|
Abstract
Pulmonary fibrosis is a common response to various insults or injuries to the lung. Although there are various initiating factors or causes, the terminal stages are characterized by proliferation and progressive accumulation of connective tissue replacing normal functional parenchyma. The pathogenesis of pulmonary fibrosis includes endothelial and epithelial cell injury, production of inflammatory cells and their mediators, and fibroblast activation. Conventional therapy consisting of glucocorticoids or cytotoxic drugs is usually ineffective in preventing progression of the disease. Further understanding of the molecular mechanisms of endothelial and epithelial cell injury, inflammatory reaction, fibroblast proliferation, collagen deposition and lung repair, should lead to the development of effective treatments against pulmonary fibrosis. Accordingly, this review summarizes recent progress made in understanding the molecular mechanisms of pulmonary fibrosis. A detailed discussion is presented regarding each of the potential new therapies which have emerged from the animal models of pulmonary fibrosis and which have been developed through advances in cellular and molecular biology.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | |
Collapse
|
28
|
Abstract
Anthrax toxin lethal factor (LF) in combination with anthrax toxin protective antigen (PA) was endocytosed and translocated to the cytosol of mammalian cells. Residues 1-255 of anthrax toxin lethal factor (LFn) was fused to a cytotoxic T lymphocyte (CTL) epitope of an influenza virus. For processing the toxins, PA must be cleaved into a 63-kDa fragment (PA63) by furin, which is a subtilisin-like processing endo-protease expressed by many eukaryotic cells. To test the ability of cells treated with the LFn fusion protein plus PA to deliver the epitope, CTL assay was performed. Two types of cell lines were identified, one was able to deliver CTL epitope while the other failed to efficiently deliver the epitope. To further elucidate the differences between these cells, the role of furin in these cells was examined. Disruption of the furin gene reduced its ability to deliver the CTL epitope. Furin expression in cells capable of efficiently delivering CTL epitope was quantitatively higher than in cells unable to deliver the epitope. The results suggest that furin plays a critical role in delivery of the CTL epitope of LFn fusion protein.
Collapse
MESH Headings
- Animals
- Anthrax/immunology
- Anthrax Vaccines/chemistry
- Anthrax Vaccines/immunology
- Anthrax Vaccines/metabolism
- Antigens, Bacterial
- Antigens, Viral/genetics
- Antigens, Viral/immunology
- Bacillus anthracis/immunology
- Bacterial Toxins/chemistry
- Bacterial Toxins/genetics
- Bacterial Toxins/immunology
- Bacterial Toxins/metabolism
- Blotting, Western
- Cells, Cultured
- Chloroquine/pharmacology
- Cytotoxicity, Immunologic/drug effects
- Epitopes, T-Lymphocyte/genetics
- Epitopes, T-Lymphocyte/immunology
- Female
- Flow Cytometry
- Furin
- Gene Deletion
- Gene Expression
- Orthomyxoviridae/genetics
- Orthomyxoviridae/immunology
- Ovalbumin/immunology
- Peptide Fragments/chemistry
- Peptide Fragments/immunology
- Peptide Fragments/metabolism
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Recombinant Fusion Proteins/chemistry
- Recombinant Fusion Proteins/metabolism
- Subtilisins/genetics
- Subtilisins/metabolism
- T-Lymphocytes, Cytotoxic/immunology
- Transfection
Collapse
Affiliation(s)
- Y Zhang
- Department of Microbiology, Kurume University School of Medicine, Fukuoka, Japan
| | | | | | | | | | | |
Collapse
|
29
|
Kuwano K, Fukuyama S, Ikegami T, Koto H, Hagimoto N, Matsuba T, Fujita N, Hara N. [An autopsy case of idiopathic interstitial pneumonia with diffuse alveolar hemorrhage due to acute exacerbation]. Nihon Kokyuki Gakkai Zasshi 2001; 39:787-91. [PMID: 11828736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
There has hitherto been no report describing idiopathic interstitial pneumonia associated with diffuse alveolar hemorrhage, but we herein report one such rare case. A 75-year-old man who had received a diagnosis of idiopathic interstitial pneumonia had been followed in our hospital since 1995, and had been treated with cyclophosphamide since September 1999. He discontinued taking cyclophosphamide without informing us, and two months later he was admitted to our hospital with deterioration of dyspnea on September 13, 2000. Since chest radiography and CT findings demonstrated alveolar infiltrates in the right middle lung field, he was treated with antibiotic agents. Although no deterioration of symptoms occurred, on September 14 he began to suffer rapidly progressive dyspnea accompanied with production of bloody sputum, which eventually developed into full-blown hemoptysis in the evening of September 15. He died of respiratory failure early the next morning. The autopsy findings demonstrated diffuse alveolar hemorrhage, diffuse alveolar damage, interstitial pneumonia, and pulmonary fibrosis.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashiku, Fukuoka 812-8582, Japan
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Arai M, Minatoguchi S, Kumada H, Uno Y, Nishida Y, Hashimoto K, Wang N, Takemura G, Fujiwara T, Higashioka M, Kuwano K, Fujiwara H. Role of protein kinase C in the reduction of infarct size by N-methyl-1-deoxynojirimycin, an alpha-1,6-glucosidase inhibitor. Br J Pharmacol 2001; 133:635-42. [PMID: 11429386 PMCID: PMC1572825 DOI: 10.1038/sj.bjp.0704107] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Preischaemic treatment with N-methyl-1-deoxynojirimycin (MOR-14), an alpha-1,6-glucosidase inhibitor, attenuates glycogenolysis and lactate accumulation during ischaemia and markedly reduces infarct size in rabbit hearts. In the present study, we have investigated whether protein kinase C (PKC), a principal mediator of ischaemic preconditioning, is also involved in the cardioprotective effect of MOR-14. To assess the effect of PKC inhibition on infarct size in MOR-14-treated hearts, 38 rabbits were subjected to 30 min of ischaemia followed by 48 h of reperfusion. Infarct size, as a per cent of area at risk, was significantly smaller in rabbits administered 100 mg kg(-1) of MOR-14 10 min before ischaemia (17+/-2%, n=10), than in a control group (46+/-5%, n=10). This beneficial effect of MOR-14 was abolished when 5 mg kg(-1) of chelerythrine, a PKC inhibitor, was given 10 min prior to MOR-14 injection (39+/-4%, n=10), although chelerythrine alone did not alter infarct size (43+/-4%, n=8). Further, chelerythrine had no effect on MOR-14-induced attenuation of glycogen breakdown and lactate accumulation in hearts excised at 30 min of ischaemia. Immunoblot analysis of PKC in homogenates of Langendorff-perfused rabbit hearts revealed that MOR-14 significantly increased levels of PKC-epsilon in the particulate fraction at 20 and 30 min of ischaemia and in the cytosolic fraction at 30 min of ischaemia. Taken as a whole, our data suggest that PKC acts downstream of the inhibition of glycogenolysis by MOR-14 to reduce infarct size. Thus, activation of PKC is a more direct mediator of the cardioprotection afforded by MOR-14 than is inhibition of glycogenolysis.
Collapse
Affiliation(s)
- M Arai
- The 2nd Department of Medicine, Gifu University School of Medicine, Gifu, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Hara N. Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. Am J Physiol Lung Cell Mol Physiol 2001; 280:L1128-37. [PMID: 11350791 DOI: 10.1152/ajplung.2001.280.6.l1128] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We previously demonstrated essential roles of the Fas-Fas ligand (FasL) pathway in bleomycin-induced pneumopathy in mice. T lymphocytes and natural killer cells express FasL on activation and use it as a cytotoxic effector molecule. Because interleukin (IL)-12 is known to play a critical role in cell-mediated immunity, we investigated whether anti-IL-12 antibody treatment suppresses the development of this model. The anti-IL-12 antibody treatment decreased the number of apoptotic cells and the degree of inflammation and fibrosis in lung tissue. The results of RT-PCR showed that IL-12p40, IL-12 receptor (R) β2, interferon-γ, tumor necrosis factor-α and FasL mRNAs were upregulated after bleomycin instillation. The upregulation of FasL, IL-12Rβ2, and tumor necrosis factor-α mRNA expression in lung tissue was suppressed by anti-IL-12 antibody treatment. The results of enzyme-linked immunosorbent assay showed that the levels of IL-12p40, but not of IL-12p70, were increased in lung tissue after bleomycin instillation. Although the increase in IL-12Rβ2 mRNA levels suggests that the T helper type 1 cell response may participate in lung injury, the increase in IL-12p40 supports T helper type 2 cell predominance in the fibrotic process of this model. The administration of anti-IL-12 antibody could be a novel therapy against lung injury and pulmonary fibrosis.
Collapse
Affiliation(s)
- T Maeyama
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Higashiku, Fukuoka 812-8582, Japan
| | | | | | | | | | | |
Collapse
|
32
|
Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Matsuba T, Yoshimi M, Inoshima I, Yoshida K, Hara N. Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17:180-9. [PMID: 11334117 DOI: 10.1183/09031936.01.17201800] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The caspase cascade is an executioner of apoptosis, mediated by Fas. Fas-associating protein with death domain (FADD) interacts with Fas and initiates apoptosis through activating caspase-8. It has previously been demonstrated that the Fas-Fas ligand pathway may be involved in the pathophysiology of idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate Fas-signalling molecules in epithelial cells in IPF. The immunohistochemistry for FADD and caspase-1 and -3 and terminal deoxynucleotidyl transferase-mediated deoxyuridinetriphosphate nick endlabelling (TUNEL) methods were performed in lung tissues from 10 patients with IPF obtained by thoracoscopic biopsy and in seven normal lung parenchyma specimens. The induction of caspases expression and activation by Fas-ligation on lung epithelial cell line A549 was also investigated. The immunoreactivity grade for FADD and caspase-1 and -3, and positive signals for TUNEL were significantly increased in epithelial cells of IPF compared with controls. Fas-ligation induced upregulation of caspase-1 and -3 expression in the nucleus and cytoplasm in A549 cells. Procaspase-1, -3, and -8 were activated in apoptotic cells, but not in viable cells. Although direct measurement of the caspase activity in lung epithelial cells of idiopathic pulmonary fibrosis could not be made, these results suggest that the Fas-signalling pathway is upregulated in lung epithelial cells of idiopathic pulmonary fibrosis.
Collapse
Affiliation(s)
- T Maeyama
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Kuwano K, Kunitake R, Maeyama T, Hagimoto N, Kawasaki M, Matsuba T, Yoshimi M, Inoshima I, Yoshida K, Hara N. Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2001; 280:L316-25. [PMID: 11159011 DOI: 10.1152/ajplung.2001.280.2.l316] [Citation(s) in RCA: 125] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Caspases have been implicated in the effector process of apoptosis in several systems including the Fas-Fas ligand pathway. We previously demonstrated that excessive apoptosis of lung epithelial cells and the Fas-Fas ligand pathway were essential in the pathogenesis of bleomycin-induced pneumopathy in mice. Therefore, the purpose of this study was to investigate whether a caspase inhibitor could prevent the development of this model. The expression of caspase-1 and caspase-3 was upregulated on lung epithelial cells, alveolar macrophages, and infiltrating inflammatory cells in this model. We demonstrated that a broad-spectrum caspase inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, decreased the caspase-1- and caspase-3-like activity, the number of apoptotic cells, the pathological grade of lung inflammation and fibrosis, and the hydroxyproline content in lung tissues in this model. We conclude that caspase inhibitors could be a new therapeutic approach against lung injury and pulmonary fibrosis.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Higashiku, Fukuoka 812-8582, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abe J, Kitade Y, Kuwano K, Watanabe T, Saga N. Isolation of a cDNA encoding a homologue of ribosomal protein L36 in a marine green alga, Enteromorpha compressa. DNA Res 2000; 7:309-13. [PMID: 11089913 DOI: 10.1093/dnares/7.5.309] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J Abe
- Center for Advanced Technology, Tokai University, Shizuoka, Japan
| | | | | | | | | |
Collapse
|
35
|
Ishibashi H, Kuwano K, Takahama K. Inhibition of the 5-HT(1A) receptor-mediated inwardly rectifying K(+) current by dextromethorphan in rat dorsal raphe neurones. Neuropharmacology 2000; 39:2302-8. [PMID: 10974313 DOI: 10.1016/s0028-3908(00)00092-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The effect of dextromethorphan (DM) on the inwardly rectifying K(+) currents mediated by 5-HT(1A) receptors in acutely dissociated dorsal raphe (DR) neurones of rats was studied using nystatin-perforated patch and conventional whole-cell patch recording configurations under voltage-clamp conditions. DM rapidly and reversibly inhibited the K(+) currents induced by 10(-7) M 5-HT in a concentration-dependent manner with a half-maximum inhibitory concentration of 1.43 x 10(-5) M. The inhibitory effect of DM was neither voltage- nor use-dependent. DM caused a suppression of the maximum response of the 5-HT concentration-response curve, thus suggesting a non-competitive type of inhibition. In neurones perfused intracellularly with a pipette-solution containing the nonhydrolyzable GTP analog GTPgammaS, 5-HT activated K(+) currents in an irreversible manner. DM suppressed the current irreversibly activated by intracellular GTPgammaS even in the absence of the agonist. DM also inhibited the inwardly rectifying K(+) currents regulated by alpha(2)-adrenoceptors in freshly isolated rat locus coeruleus neurones. These results suggest that DM may inhibit the G-protein coupled inwardly rectifying K(+) channels, but not the neurotransmitter receptors, in the central nervous system.
Collapse
Affiliation(s)
- H Ishibashi
- Department of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, 862-0973, Kumamoto, Japan
| | | | | |
Collapse
|
36
|
Kawasaki M, Kuwano K, Hagimoto N, Matsuba T, Kunitake R, Tanaka T, Maeyama T, Hara N. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. Am J Pathol 2000; 157:597-603. [PMID: 10934162 PMCID: PMC1850133 DOI: 10.1016/s0002-9440(10)64570-1] [Citation(s) in RCA: 188] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 05/19/2000] [Indexed: 11/29/2022]
Abstract
LPS (lipopolysaccharide) is one of the major factors that induce acute lung injury. Recently, it was reported that LPS induced disseminated endothelial apoptosis, preceding nonendothelial tissue damage. Caspases play important roles in apoptosis, including tumor necrosis factor-alpha-induced apoptosis, in several systems. We therefore investigated whether the injection of a caspase inhibitor prevents LPS-induced apoptosis and acute lung injury in mice. LPS (30 mg/kg) was administered intravenously to Institute for Cancer Research mice. Electron microscopic findings demonstrated characteristic features of apoptosis in endothelial cells and alveolar epithelial cells. The caspase-3 activity and the number of terminal dUTP nick-end labeling-positive cells in lung tissues were significantly increased after LPS administration. Benzyloxycarbonil-Val-Ala-Asp fluoromethylketone (Z-VAD.fmk), which is a broad-spectrum caspase inhibitor, was injected before and after the administration of LPS. The injection of Z-VAD.fmk suppressed the caspase-3 activity in lung tissues, and significantly decreased the number of terminal dUTP nick-end labeling-positive cells. Furthermore, the survival rate of mice was prolonged significantly by the injection of Z-VAD.fmk. These results indicate that apoptosis may play an important role in acute lung injury, and thus that inhibition of caspase activity may constitute a new therapeutic approach for treatment of this disease.
Collapse
Affiliation(s)
- M Kawasaki
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Kuwano K, Kawasaki M, Maeyama T, Hagimoto N, Nakamura N, Shirakawa K, Hara N. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest 2000; 118:451-8. [PMID: 10936140 DOI: 10.1378/chest.118.2.451] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
STUDY OBJECTIVES The Fas-Fas ligand (FasL) pathway is a representative system of apoptosis-signaling receptor molecules. We previously described that this pathway may play an important role in the pathogenesis of fibrosing lung diseases. In this study, we hypothesized that soluble form of Fas (sFas) and FasL (sFasL) may also be associated with this disorder. MEASUREMENTS AND RESULTS We measured sFas and sFasL levels in BAL fluid (BALF) from patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia associated with collagen vascular diseases (CVD-IP), and bronchiolitis obliterans organizing pneumonia (BOOP), using enzyme-linked immunosorbent assay. BALF from all patients was obtained before prednisolone therapy. sFasL levels were relatively increased in IPF patients (p = 0.084), and significantly increased in CVD-IP patients (p < 0.05) and BOOP patients (p < 0.05), compared with control subjects. BALF sFasL levels were elevated in the IPF or CVD-IP subgroups with an indication for prednisolone therapy, compared with those without an indication for therapy. The BALF sFasL level in IPF patients was correlated with the number of total cells and lymphocytes. The BALF sFasL level in BOOP patients was relatively or significantly correlated with the number of total cells or lymphocytes, respectively. The BALF sFas level was significantly increased in BOOP patients, but not in IPF or CVD-IP patients. CONCLUSIONS We conclude that BALF sFasL levels may be associated with the accumulation of inflammatory cells and reflect the degree of lymphocyte alveolitis in IPF. The elevation of sFasL may be associated with the deterioration of IPF and CVD-IP. The elevation of the BALF sFas level may abrogate the cytotoxicity of FasL in BOOP patients, which may be associated with better prognosis of BOOP, compared with IPF or CVD-IP.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | |
Collapse
|
38
|
Kuwano K, Hagimoto N, Kawasaki M, Nakamura N, Shirakawa K, Maeyama T, Hara N. Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis. Int Arch Allergy Immunol 2000; 122:209-15. [PMID: 10899765 DOI: 10.1159/000024399] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Hypersensitivity pneumonitis (HP) is characterized by a lymphocytic alveolitis and loosely formed granulomas in lung biopsy specimens. HP improves or disappears altogether after cessation of antigen exposure. The Fas-Fas ligand (FasL) system is one of the representative systems of apoptosis-signaling receptor molecules, and is involved in various inflammatory diseases. We hypothesized that the Fas-FasL system may be associated with this disorder. METHODS We examined the expression of FasL and Fas proteins in lung tissues from patients with HP using immunohistochemistry. We also measured the soluble form of FasL (sFasL) and sFas levels in serum and bronchoalveolar lavage fluid (BALF) from patients with HP using enzyme-linked immunosorbent assay (ELISA). Furthermore, we also measured the cytotoxic activity of BALF sFasL in vitro. RESULTS FasL was detected in infiltrating mononuclear cells, and Fas was detected in infiltrating mononuclear cells, alveolar macrophages, and epithelioid cells in HP, whereas FasL was not detected and Fas was detected in few alveolar macrophages in controls. The levels of sFasL and sFas in BALF, but not in serum, were significantly increased in HP compared with controls. BALF of HP that included high levels of sFasL had no cytotoxic activity for bronchiolar epithelial cells in vitro. CONCLUSIONS In HP, there is an upregulation of FasL and Fas in lung tissues. Since there is no incidence of apoptosis and no cytotoxic activity for lung epithelial cells in BALF from patients with HP, the increased levels of BALF sFasL and sFas may reflect the activation and sequestration of inflammatory cells rather than apoptosis.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | |
Collapse
|
39
|
Kawasaki M, Kuwano K, Nakanishi Y, Hagimoto N, Takayama K, Pei XH, Maeyama T, Yoshimi M, Hara N. Analysis of Fas and Fas ligand expression and function in lung cancer cell lines. Eur J Cancer 2000; 36:656-63. [PMID: 10738132 DOI: 10.1016/s0959-8049(99)00332-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The aim of this study was to investigate the expression of Fas and Fas ligand (FasL) and to determine the significance of these molecules in lung cancer cell lines. Immunoblotting, RT-PCR and flow cytometric analyses were carried out to measure the expression of Fas and FasL and to examine their interactions and effects on cell growth and apoptosis. Fas and FasL were co-expressed in most of the cell lines but to varying degrees. Apoptosis induced by the agonistic anti-Fas antibody was significantly correlated with Fas expression (P=0.0075), whereas cisplatin-induced apoptosis was not. Upregulation of Fas and FasL expression by the administration of cisplatin was found in 7 of 11 (64%) and 9 of 11 (82%) cell lines, respectively. However, cisplatin-induced apoptosis was not suppressed by antagonistic anti-FasL antibody. Thus, our data indicated that Fas and FasL were co-expressed in lung cancer cell lines, and that Fas ligation induced by agonistic anti-Fas antibody is functional and induced apoptosis that was dependent on the levels of Fas expression. In contrast, Fas-FasL interactions appeared to be non-functional. Furthermore, our results suggest that cisplatin-induced apoptosis in lung cancer cells was independent of the Fas-FasL interaction.
Collapse
Affiliation(s)
- M Kawasaki
- Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Kuwano K, Hagimoto N, Tanaka T, Kawasaki M, Kunitake R, Miyazaki H, Kaneko Y, Matsuba T, Maeyama T, Hara N. Expression of apoptosis-regulatory genes in epithelial cells in pulmonary fibrosis in mice. J Pathol 2000; 190:221-9. [PMID: 10657022 DOI: 10.1002/(sici)1096-9896(200002)190:2<221::aid-path495>3.0.co;2-j] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Up-regulation of Fas and Fas ligand and excessive apoptosis of bronchiolar and alveolar epithelial cells were identified in bleomycin-induced pulmonary fibrosis in mice. This study hypothesized that apoptosis-regulatory genes other than Fas-Fas ligand, such as p53, p21 (Waf1/Cip1), bcl-2, bcl-x, and bax, may also participate in epithelial cell apoptosis in this model. The expression of these genes was assessed by reverse transcription polymerase chain reaction (RT-PCR), RT in situ PCR, or immunohistochemistry. The expression of p53 and p21 mRNA was concurrently up-regulated in the alveolar epithelial cells at 1 h to 7 days after intratracheal instillation of bleomycin. The expression of bcl-2 mRNA was weakly up-regulated at 1 h to 14 days, while the expression level of bcl-2 protein was not changed. The expression of bcl-x(L) and bax mRNA was strongly up-regulated at 1 h to 7 days. The expression of bcl-x protein was up-regulated in lymphocytes and macrophages, whereas bax protein was up-regulated in both epithelial and inflammatory cells. It is concluded that epithelial cell apoptosis in this model may also be induced by the up-regulation of p53 and bax and by the imbalance between apoptosis-inducible and -inhibitory genes, in addition to the up-regulation of the Fas-Fas ligand pathway.
Collapse
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
A high-pressure vessel designed for use with commercial magnetic resonance imaging equipment at up to 40 MPa of pressure was used and tested. Special features of the vessel are the following: 1) 12.6 mm sample chamber i.d.; 2) only non-magnetic parts; 3) visible sample from the outside; 4) resistant to corrosive chemicals, and; 5) sample could be manually translated and rotated in situ. This apparatus was demonstrated through observation of CO(2) clathrate-hydrate growth in a water droplet injected into liquid CO(2) at 20 MPa.
Collapse
Affiliation(s)
- S Hirai
- Research Center for Carbon Recycling & Utilization, Tokyo Institute of Technology 2-12-1, O-okayama, Meguro-ku, Tokyo, Japan.
| | | | | | | | | |
Collapse
|
42
|
Kuwano K, Hara N. Signal transduction pathways of apoptosis and inflammation induced by the tumor necrosis factor receptor family. Am J Respir Cell Mol Biol 2000; 22:147-9. [PMID: 10657934 DOI: 10.1165/ajrcmb.22.2.f178] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | |
Collapse
|
43
|
Inoue H, Aizawa H, Nakano H, Matsumoto K, Kuwano K, Nadel JA, Hara N. Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med 2000; 161:249-56. [PMID: 10619828 DOI: 10.1164/ajrccm.161.1.9804096] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Nitric oxide (NO) is increased in exhaled air of asthmatics. We hypothesized that endogenous NO contributes to airway inflammation and hyperresponsiveness, and that interleukin-8 (IL-8) might be involved in this mechanism. In human transformed bronchial epithelial cells in vitro, NO donors increased IL-8 production dose-dependently. In addition, tumor necrosis factor-alpha (TNF-alpha) plus IL-1beta plus interferon-gamma (IFN-gamma) increased IL-8 in culture supernatant of epithelial cells; the combination of NO synthase (NOS) inhibitors, aminoguanidine (AG) plus N(G)-nitro-L-arginine methyl ester (L-NAME) attenuated the cytokine-induced IL-8 production in epithelial cells. In guinea pigs in vivo, ozone exposure induced airway hyperresponsiveness to acetylcholine and increased neutrophils in bronchoalveolar lavage fluid (BALF), and these changes persisted for at least 5 h. Pretreatment with NOS inhibitors had no effect on airway hyperresponsiveness or neutrophil accumulation immediately after ozone, but significantly inhibited the changes 5 h after ozone. NOS inhibitors also attenuated the increases of nitrite/nitrate levels in BALF and the IL-8 mRNA expression in epithelial cells and in neutrophils in guinea pig airways 5 h after ozone. These results suggest that endogenous NO may play an important role in the persistent airway inflammation and hyperresponsiveness after ozone exposure, presumably partly through the upregulation of IL-8.
Collapse
Affiliation(s)
- H Inoue
- Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | |
Collapse
|
44
|
Kaneko Y, Kuwano K, Kunitake R, Kawasaki M, Hagimoto N, Hara N. B7-1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia. Eur Respir J 2000; 15:49-55. [PMID: 10678620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Interstitial lung diseases are thought to be associated with the infiltration of activated T-lymphocytes. To induce an effective immune response, antigen-presenting cells have to not only present antigenic peptide with major histocompatibility complex (MHC) molecules to T-lymphocytes but also express B7 molecules. Therefore, the expression of B7-1, B7-2 and class II MHC molecules was investigated in lung tissues from patients with idiopathic pulmonary fibrosis (IPF) and bronchiolitis obliterans-organizing pneumonia (BOOP), and in normal lung parenchyma as a control, using immunohistochemical localization. B7-1 and B7-2 were aberrantly expressed in bronchiolar and alveolar epithelial cells, and class II MHC molecules were also aberrantly expressed in bronchiolar epithelial cells in IPF. B7-1 was aberrantly expressed in bronchiolar epithelial cells in BOOP. There was no significant difference in the expression of these proteins in alveolar macrophages between IPF and control subjects. However, B7-2 and class II MHC molecule expression in alveolar macrophages was decreased in BOOP compared with that in control subjects. Expression of CD28 and CTLA4, receptors for B7 molecules, was detected in infiltrating lymphocytes in lung tissues in IPF and BOOP. It was concluded that bronchiolar and alveolar epithelial cells may actively participate in the pathophysiology of idiopathic pulmonary fibrosis through the aberrant expression of B7 and class II major histocompatibility complex molecules. The dysregulation of these molecules in epithelial cells may lead to the activation of autoreactive T-lymphocytes, which might contribute to the pathogenesis of fibrosing lung diseases.
Collapse
Affiliation(s)
- Y Kaneko
- Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Higashiku, Fukuoka, Japan
| | | | | | | | | | | |
Collapse
|
45
|
Kaneko Y, Kuwano K, Kunitake R, Kawasaki M, Hagimoto N, Hara N. B7‐1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia. Eur Respir J 2000. [DOI: 10.1034/j.1399-3003.2000.15a10.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
46
|
Kaneko Y, Kuwano K, Kunitake R, Kawasaki M, Hagimoto N, Hara N. B7-1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia. Eur Respir J 2000. [DOI: 10.1183/09031936.00.15104900] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
47
|
Hagimoto N, Kuwano K, Kawasaki M, Yoshimi M, Kaneko Y, Kunitake R, Maeyama T, Tanaka T, Hara N. Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am J Respir Cell Mol Biol 1999; 21:436-45. [PMID: 10460762 DOI: 10.1165/ajrcmb.21.3.3397] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Epithelial cell injury is the common manifestation of lung injury. Contributing to such injury of epithelial cells is apoptosis. Although apoptosis is part of the normal process of epithelial renewal, in excess it is pathologic. We previously demonstrated the excessive apoptosis of lung epithelial cells and the upregulation of Fas and Fas ligand (FasL) in fibrosing lung diseases. We also showed that inhalation of anti-Fas antibody induced lung injury and fibrosis in mice. Interleukin (IL)-8 is one of the most important cytokines in the pathophysiology of acute lung injury and pulmonary fibrosis. In this study we investigated whether Fas ligation induces IL-8 secretion in addition to apoptosis in bronchiolar epithelial cells in vitro. Bronchiolar epithelial cells underwent apoptosis and also secreted IL-8 in response to tumor necrosis factor (TNF)-alpha or Fas ligation. New gene expression and protein synthesis were not necessary for Fas ligation- and TNF-alpha- mediated apoptosis, but were necessary for IL-8 secretion. We further found that Fas ligation induced activation of nuclear factor-kappa B. We conclude that the Fas/FasL pathway not only mediates apoptosis but also plays a proinflammatory role, and that stimulation of the Fas/FasL pathway in bronchiolar epithelial cells leads to IL-8 production, which may amplify the inflammatory cascade in lung injury and pulmonary fibrosis.
Collapse
Affiliation(s)
- N Hagimoto
- Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Kaneko Y, Kuwano K, Kunitake R, Kawasaki M, Hagimoto N, Miyazaki H, Maeyama T, Tanaka T, Matsuba T, Hara N. Immunohistochemical localization of B7 costimulating molecules and major histocompatibility complex class II antigen in pulmonary sarcoidosis. Respiration 1999; 66:343-8. [PMID: 10461083 DOI: 10.1159/000029405] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Alveolar macrophages (AM) of sarcoidosis have an enhanced capacity to mediate antigen-induced T lymphocyte proliferation. To induce an effective immune response, antigen-presenting cells have to not only present antigenic peptide with MHC molecules to T lymphocytes, but also express B7 costimulating molecules. OBJECTIVE The purpose of this study was to investigate the expression of B7 and MHC molecules in lung tissues from patients with sarcoidosis. METHODS We performed immunohistochemistry for B7-1, B7-2 and MHC class II antigens using transbronchial lung biopsy specimens obtained from patients with sarcoidosis and normal lung parenchyma obtained by lobectomy for solitary pulmonary nodule as controls. RESULTS B7-1, B7-2 and MHC class II antigen were expressed in epithelioid cells in granulomas in 14 (93.3%), 2 (13.3%) and 9 (60.0%) of 15 patients with sarcoidosis, respectively. These were also expressed in AM in 14 (93. 3%), 5 (33.3%) and 12 (80.0%) of 15 patients with sarcoidosis, respectively. The positivity of B7-1 was significantly higher than that of B7-2 in both epithelioid cells and AM in sarcoidosis (p < 0. 01). Positive signals for B7-1, B7-2 and MHC class II antigen were also found in AM in 9 (90%), 8 (80%) and 8 (80%) of 15 of controls, respectively. However, the intensity of positive signals for B7-1, but not B7-2 or MHC class II antigen in AM was significantly increased in sarcoidosis compared to controls (p < 0.05). CONCLUSIONS These results suggested that epithelioid cells in granulomas and AM from patients with sarcoidosis had the capability to act as accessory cells and that the accessory function of these cells was shifted to B7-1 rather than B7-2 in sarcoidosis.
Collapse
Affiliation(s)
- Y Kaneko
- Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushi University, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Kuwano K. [Respiratory tract diseases and apoptosis]. Fukuoka Igaku Zasshi 1999; 90:333-8. [PMID: 10576990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Affiliation(s)
- K Kuwano
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University
| |
Collapse
|
50
|
Hara N, Kotho H, Kuwano K. [Cancer and thromboembolism]. Nihon Rinsho 1999; 57:1648-52. [PMID: 10429472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Thromboembolism is the most common complication in patients with malignant diseases. The recent studies have indicated that the pathogenesis of thromboembolism in cancer is associated with the hemostatic alternations induced by cancer cells and cancer-stimulated mononuclear cells: injury to the endothelial lining of blood vessels, activation of blood coagulation and depression of anticoagulant function. Although thromboembolism is generally observed in patients with advanced cancer, it may occur in patients with occult cancer. In the treatment of thromboembolism, the administration of low molecular heparin has been introduced recently, in addition to the immediate and intensive treatment of cancer.
Collapse
Affiliation(s)
- N Hara
- Research Institute for Diseases of the Chest, Faculty of Medicine, Kyushu University
| | | | | |
Collapse
|